Trade-Ideas LLC identified

Revance Therapeutics

(

RVNC

) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Revance Therapeutics as such a stock due to the following factors:

  • RVNC has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $20.8 million.
  • RVNC has traded 151,475 shares today.
  • RVNC is down 3.4% today.
  • RVNC was up 40.6% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in RVNC with the Ticky from Trade-Ideas. See the FREE profile for RVNC NOW at Trade-Ideas

More details on RVNC:

Revance Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. Currently there are 3 analysts that rate Revance Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TST Recommends

The average volume for Revance Therapeutics has been 163,300 shares per day over the past 30 days. Revance has a market cap of $644.5 million and is part of the health care sector and drugs industry. Shares are up 121.9% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Revance Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow.

Highlights from the ratings report include:

  • REVANCE THERAPEUTICS INC' earnings per share from the most recent quarter came in slightly below the year earlier quarter. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, REVANCE THERAPEUTICS INC reported poor results of -$3.10 versus -$0.57 in the prior year. For the next year, the market is expecting a contraction of 15.2% in earnings (-$3.57 versus -$3.10).
  • The change in net income from the same quarter one year ago has exceeded that of the Pharmaceuticals industry average, but is less than that of the S&P 500. The net income has significantly decreased by 26.3% when compared to the same quarter one year ago, falling from -$13.30 million to -$16.81 million.
  • Net operating cash flow has declined marginally to -$12.49 million or 2.73% when compared to the same quarter last year. Despite a decrease in cash flow REVANCE THERAPEUTICS INC is still fairing well by exceeding its industry average cash flow growth rate of -45.83%.
  • Compared to other companies in the Pharmaceuticals industry and the overall market, REVANCE THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Despite the stagnant revenue growth, the company outperformed against the industry average of 6.2%. Since the same quarter one year prior, revenues have remained constant. Even though the company's revenue remained stagnant, the earnings per share decreased.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.